世界中医药
文章摘要
引用本文:孟宪璞,肖丽梅,张素霞,李静,李开丽,连丽英,安国辉.郭连澍教授经验方“丹栀通竹方”治疗中风后抑郁症的临床研究[J].世界中医药,2017,(04):.  
郭连澍教授经验方“丹栀通竹方”治疗中风后抑郁症的临床研究
Clinical Study of “Danzhi Tongzhu” in the Treatment of Post-stroke Depression
投稿时间:2017-01-06  
DOI:10.3969/j.issn.1673-7202.2017.04.032
中文关键词:  丹栀通竹方  中风  抑郁  BDNF
English Keywords:Danzhi Tongzhu  Stroke  Depression  BDNF
基金项目:河北省中医药管理局科研计划(编号:20140154)
作者单位
孟宪璞,肖丽梅,张素霞,李静,李开丽,连丽英,安国辉 新乐市中医医院针灸科新乐050700 
摘要点击次数: 1126
全文下载次数: 1040
中文摘要:
      目的:观察关“丹栀通竹方”治疗中风后抑郁症的临床。方法:选取2015年3月至2016年2月新乐市中医医院针灸科、康复科门诊、中风病病房收治的60例中风后抑郁患者,按就诊顺序编随机数字表法进行随机分为治疗组和对照组,每组30例。对照组在内科常规治疗基础上,口服盐酸氟西汀(20 mg,1次/d,治疗组在内科常规治疗基础上给予丹栀通竹方加减治疗。治疗前、治疗30 d和治疗60 d采用Fugl-Mayer评估量表(FMA)量表评估患者的偏瘫肢体运动功能;汉密顿抑郁量表(HAMD)量表评分对中风后患者进行抑郁评分评估;运用改良日常生活活动量表(mBI)评分以评估患者的生活质量及采用酶联免疫吸附试验(ELISA)检测脑源性神经营养因子(BDNF)。结果:2组治疗后FMA、mBI评分和BDNF均高于治疗前(P<0.05);与对照组比较,治疗组治疗30 d的FMA、mBI评分和BDNF均差异无统计学意义(P>0.05),治疗60 d的FMA、mBI评分和BDNF均较高(P<0.05)。HAMD评分结果与之相反,BDNF的表达情况与HAMD量表评分呈负相关,Pearson相关系数为-0.949,P=0.000<0.05。结论:丹栀通竹方可明显改善PSD抑郁症状,并因此更进一步协助患者躯体功能恢复,而该方发挥疗效可能与上调BDNF有关。
English Summary:
      To observe the effect of “Danzhi Tongzhu” in clinical treatment of depression after stroke. Methods:A total of 60 patients with post-stroke depression admitted in departments of acupuncture, rehabilitation and stroke disease of Xinle Hospital of Traditional Chinese Medicine from March 2015 to February 2016 were randomly divided into a treatment group and a control group according to the order of visits, with 30 patients in each group. Patients in the control group were given oral administration of fluoxetine hydrochloride (20 mg, 1 times a day) on the basis of routine medical treatment, while patients in the treatment group were given Danzhi Tongzhu on the same basis. Before treatment, 30 days and 60 days after treatment, Fugl-Mayer assessment scale (FMA) was used to assess the motor function of hemiplegic limbs of patients; the Hamilton depression scale (HAMD) was used to evaluate the depression of patients; activities of daily living scale (mBI) was used to assess the quality of life of patients and enzyme-linked immunosorbent assay (ELISA) was used to detect the patients’ brain-derived neurotrophic factor (BDNF). Results:After treatment, the FMA, mBI score and BDNF were all higher than those before treatment (P<0.05). Compared with the control group, there was no statistically significant difference in the FMA, mBI score and BDNF in the treatment group (P>0.05) 30 days after treatment, while 60 days after treatment, the FMA, mBI score and BDNF were higher (P<0.05). By contrast, the HAMD score was negatively correlated with the BDNF expression and the HAMD scale score, and the correlation coefficient of Pearson was-0.949, P=0.000<0.05. Conclusion:Danzhi Tongzhu can significantly improve PSD symptoms of depression, and therefore further assist patients with recovery of body function, and the effect may be related to the increase in BDNF.
查看全文  查看/发表评论  下载PDF阅读器